Helius Therapeutics
Helius Therapeutics is a vertically integrated New Zealand medicinal cannabis company that cultivates, extracts, and GMP-manufactures pharmaceutical-grade cannabis products for patients via pharmacy prescription, clinics, and export partners in Australia and Denmark.
- Company typePrivate
- Founded2018
- HeadquartersEast Tamaki, New Zealand
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
Helius Therapeutics firmographics
Firmographics- Name
- Helius Therapeutics
- Legal name
- Helius Therapeutics
- Website
- https://helius.co.nz
- Company type
- Private
- Founded year
- 2018
- Operating status
- Closed
- Headcount range
- 1–10 employees
- Short description
- Helius Therapeutics is a vertically integrated New Zealand medicinal cannabis company that cultivates, extracts, and GMP-manufactures pharmaceutical-grade cannabis products for patients via pharmacy prescription, clinics, and export partners in Australia and Denmark.
- Ownership category
- akta.pro rank
Helius Therapeutics industry classification
Industry- Product category
- Medicinal Cannabis Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Helius Therapeutics is headquartered
LocationHeadquarters
- HQ city
- East Tamaki
- HQ country
- New Zealand
- HQ region
- Oceania
Offices2 records
Markets served
Helius Therapeutics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Prescription Medicinal Cannabis Products: Products sold through pharmacies via prescription from doctors. Patients obtain products like any other medication through a prescription model.
- International Export Sales: Partnerships with distributors in Australia (Novachem) and Denmark (Balancial Denmark) to supply GMP-certified medicinal cannabis extracts and flower products to international patients.
- Wholesale/B2B Supply: Supply agreements with other licensed operators including the five-year deal with Puro for organic medicinal cannabis supply.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Helius Therapeutics product offering
Product offeringCore offering
Helius Therapeutics is a vertically integrated medicinal cannabis company that breeds, cultivates, extracts, and GMP-manufactures cannabinoid-based pharmaceutical products in New Zealand. Its portfolio includes cannabis oil extracts delivered as soft gel caplets, sublingual drops, and topical creams (e.g., THC25:CBD25 Oral Solution, Helius Assist), distributed domestically via prescription through pharmacies and exported through distribution partners in Australia and Denmark.
Product overview
Helius Therapeutics is a vertically integrated medicinal cannabis company operating as a single unified product portfolio. Their core offerings include medicinal cannabis extracts (oil-based formulations), oral solutions such as THC25:CBD25 Oral Solution, and products like Helius Assist. These products are manufactured at their 8,800sqm Auckland facility using indoor controlled cultivation, CO2 and cryo-ethanol extraction, and GMP-certified production processes. All products are distributed through prescription via doctors and pharmacies in New Zealand, with export partnerships extending to Australia and Denmark.
Differentiator
Problem solved
Functional benefit
Brands
- Helius Assist: Medicinal cannabis extract product
Products and services
- Helius THC25:CBD25 Oral Solution A balanced THC and CBD oral solution formulation providing consistent dosing of cannabinoid extracts for medicinal cannabis patients in New Zealand, dispensed by prescription through pharmacies.
- Helius Assist A medicinal cannabis product offering from Helius listed within patient access materials as part of the company's therapeutic solutions portfolio for prescription patients.
- Medicinal Cannabis Extracts Cannabis oil extracts formulated into soft gel caplets, sublingual drops, and topical creams; CBD-dominant with minimal psychoactive effects, produced under EU-GMP standards for prescription patients and export markets.
Quantifiable outcome
- Patients in New Zealand gained access to locally-made cannabis medicines in October 2021
- +1 more outcomes
Companies that use Helius Therapeutics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Helius Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Helius Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- NovachemcoreStrategic partnership with Novachem as sponsor and primary distributor for Helius Therapeutics' NZ-grown, NZ-made, GMP-certified medicinal cannabis products in Australia. Novachem enables wider range of product options for Australian patients.
- Balancial DenmarkcoreStrategic partnership with Balancial Denmark to launch premium medicinal cannabis extracts in the Danish market. Partnership merges Helius' advanced cultivation and extraction expertise with Balancial's strong local presence, addressing growing demand for medicinal cannabis in Denmark with approximately 10,000 patients.
- MCinfo.com (DATAPHARM)minorEducation sponsor of MCinfo.com, a dedicated medicinal cannabis information service. Helius sponsors prescriber education to improve healthcare professional knowledge and patient access.
- PurocoreFive-year multi-million dollar supply agreement for Puro to supply over 10 tonnes of organic medicinal cannabis to Helius, equivalent to approximately five shipping containers of dried cannabis flower. Puro is New Zealand's largest cannabis grower and only certified organic grower in Australasia.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Helius Therapeutics competitors and assessment
Company assessmentDirect peers
- Cann Group Limited: Australian medicinal cannabis cultivator and manufacturer with GMP-certified production facilities supplying Australian and European patients. Highly comparable as an APAC-headquartered GMP cannabis producer using similar cultivation-to-extraction model.
- Little Green Pharma: Vertically integrated Australian medicinal cannabis company producing GMP-certified flower and oil products for domestic and European export markets. Directly comparable in scale, vertical integration, and EU-GMP-driven export strategy to Helius.
- Bod Australia: Listed Australian company developing and commercialising medicinal cannabis and hemp-derived therapeutic products. Comparable as an APAC medicinal cannabis product developer with HCP-facing distribution.
- Zelira Therapeutics: Clinically-driven medicinal cannabis company with operations in Australia and the US developing proprietary cannabinoid formulations. Comparable as a research-and-product-focused cannabis therapeutics firm targeting regulated pharmacy channels.
Emerging players
- Puro: New Zealand's largest cannabis grower and Australasia's only certified-organic grower, with a multi-year commercial supply agreement to Helius. Directly comparable as a NZ medicinal cannabis producer in the same regulatory scheme.
Broad incumbents
- Tilray Brands: Global cannabis leader with GMP-certified production in Canada, Portugal, Germany, and Australia exporting medicinal cannabis across Europe and Asia-Pacific. Comparable as a large incumbent supplying the same regulated medicinal cannabis channels Helius targets.
- Jazz Pharmaceuticals (GW Pharmaceuticals): Owner of the Sativex/Epidiolex cannabinoid medicine franchises, setting the regulatory benchmark for GMP cannabinoid therapeutics globally. Comparable as the established reference point for GMP-certified pharmaceutical-grade cannabis medicines.
- Aurora Cannabis: Large-scale Canadian medicinal cannabis producer with EU-GMP-certified facilities distributing into European pharmacy channels. Comparable as an EU-GMP-certified exporter competing for the same import-customer relationships Helius targeted via Balancial Denmark.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights5 records
Customer concentration
Helius Therapeutics social profiles
Digital presenceHelius Therapeutics compliance and trust
Trust signalCompliance3 records
Helius Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Helius Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Helius Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Helius Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Helius Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Helius Therapeutics
What does Helius Therapeutics do?
Helius Therapeutics is a vertically integrated medicinal cannabis company that breeds, cultivates, extracts, and GMP-manufactures cannabinoid-based pharmaceutical products in New Zealand. Its portfolio includes cannabis oil extracts delivered as soft gel caplets, sublingual drops, and topical creams (e.g., THC25:CBD25 Oral Solution, Helius Assist), distributed domestically via prescription through pharmacies and exported through distribution partners in Australia and Denmark.
Is Helius Therapeutics a public or private company?
Helius Therapeutics is a private company. It is classified as venture growth investor backed and is currently closed.
When was Helius Therapeutics founded?
Helius Therapeutics was founded in 2018. It employs 1 to 10 people.
Where is Helius Therapeutics based?
Helius Therapeutics is headquartered in East Tamaki, New Zealand, in the Oceania region.
How does Helius Therapeutics make money?
Three revenue lines are on record. Prescription Medicinal Cannabis Products are the primary driver. The others are international Export Sales and wholesale/B2B Supply.
Who are Helius Therapeutics's main competitors?
Direct peers on record are Cann Group Limited, Little Green Pharma, Bod Australia and Zelira Therapeutics. Puro is listed as an emerging player. Broad incumbents are Tilray Brands, Jazz Pharmaceuticals (GW Pharmaceuticals) and Aurora Cannabis.
Does Helius Therapeutics have an API?
No public API is recorded for Helius Therapeutics.
What industry is Helius Therapeutics in?
Helius Therapeutics's product category is Medicinal Cannabis Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.